The recent crop of new stocks runs the gamut from R&D stage biotech to a Fortune 500 spin-off with billions in revenue.
News & Analysis: Pfizer
It’s rejected a pair of drugs in the last six months.
The TV host said last week that investors should avoid Pfizer. He should listen to his own previous advice about this big pharma stock.
Coke's yield is a juicy 3% or so. But you can do better! Here are three stocks every bit as enticing, if not more so.
These five-star medicines should continue to push the industry higher in the next decade, despite the political blowback surrounding U.S. prescription drug prices.
PFE earnings call for the period ending June 30, 2019.
Sometimes even solid growth isn't enough to lift a stock's price.
Pfizer's proposed deal with Mylan is complicated. But if you're a Pfizer shareholder, here's what you need to know.
Mylan plans to merge with a spinoff from Pfizer, and Merck had more good news about its blockbuster cancer drug.
No big surprises with Pfizer's Q2 earnings results. The big surprise was a major deal with Mylan that caused the results to be announced earlier than expected.